^
    Back
    Association details:
    Biomarker:TP53 mutation + KRAS mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Manag Res
    Title:

    The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study

    Published date:
    02/09/2022
    Excerpt:
    In addition, PD-1+ AG regimen improved the OS of patients with KRAS and TP53 co-mutations (8.0months vs 10.2 months, P = 0.004)... PD-1 inhibitors combined with AG chemotherapy have shown good efficacy and safety in the first-line treatment of patients with advanced pancreatic ductal adenocarcinoma. This regimen similarly improved OS in patients with KRAS and TP53 co-mutations.
    Secondary therapy:
    gemcitabine + albumin-bound paclitaxel
    DOI:
    10.2147/CMAR.S349442